142, to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products, with an amendment in the nature of a substitute. 113, to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, with an amendment in the nature of a substitute. 79, to amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents. Special Report entitled ``Activities of the Committee on Homeland Security and Governmental Affairs during the 117th Congress''. Measures Introduced: Forty-six bills and five resolutions were introduced, as follows: S. Senate Chamber Action Routine Proceedings, pages S539– S614 Daily Digest Section (PDF 338KB) Wednesday, MaDaily Digest HIGHLIGHTS
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |